Imported tropical respiratory tract infections

Community acquired pneumonia in the tropics

PURPOSE OF REVIEW

Due to the exponential growth of international exchange, millions of travelers are exposed to respiratory pathogens in the tropics and may return ill. Community-acquired pneumonia is one of the more prevalent infections.

RECENT FINDINGS

The acquisition of infections in the tropics, including community-acquired pneumonias, has been described for several centuries. During recent decades some microorganisms have been disclosed as causative of the disease (Legionella pneumophila in 1976 and hantavirus in 1990); other microorganisms are real new pathogens that were not previously demonstrated to have a pathogenic role in humans (e.g. severe acute respiratory syndrome coronavirus producing an outbreak in 2003 and H5N1 avian influenza virus producing an increasing number of human cases over the last few years).

SUMMARY

A number of microorganisms may produce pneumonia in people who live or have traveled to tropical zones. History, including geography and epidemiology, physical exam and complementary workout are precious tools for the diagnosis, therapy and prevention. Exposure to microorganisms in tropical areas may show different patterns. A high index of suspicion, detailed investigation of travel, exposure history of the patient, and a basic understanding of the incubation periods and distribution of the various potential pathogens are imperative for the diagnosis.

Respiratory tract infections in travelers: a review of the GeoSentinel surveillance network

Respiratory tract infections are common in travelers, and improving our knowledge of risk factors associated with specific types of respiratory infections should enable implementation of better preventive strategies. Data collected by the GeoSentinel surveillance network were analyzed, and the most significant predictors for developing specific categories of respiratory infections while abroad were age, sex, season of travel, trip duration, and reason for travel. In particular, influenza was associated with travel to the Northern Hemisphere during the period of December through February, travel involving visits to friends or relatives, and trip duration of >30 days. Lower respiratory tract infections were associated with male sex and increasing age. Knowledge of the respiratory tract infections that occur in specific groups of travelers allows for the development of targeted pretravel preventive strategies to high-risk groups.

Population mobility and infectious diseases: the diminishing impact of classical infectious diseases and new approaches for the 21st century

In an increasingly globalized world, rapid population mobility and migration is reducing the differences in infectious disease epidemiology between regions of the world. The movement and relocation of populations between locations where the prevalence and incidence of infections are markedly different poses current and future challenges to those involved in clinical infectious diseases and public health program management. Historically, international attention has focused on the screening and treatment of acute infections of epidemic potential, but, as immigration significantly changes the demography of many nations, chronic infections will require increased attention. In countries with large mobile populations, the population-based burden of infections with long latency periods or significant noninfectious sequelae will make up an increasing amount of the infectious disease caseload and will require more-modern approaches than the traditional screening of arrivals. The globalization of chronic infectious disease epidemiology will require corresponding development of integrated programs to anticipate and manage these diseases in response to an increasingly mobile patient population.

Community-acquired pneumonia

Community-acquired pneumonia (CAP) remains a leading cause of morbidity and mortality worldwide and has significant financial implications for health-care systems. The epidemiology and fundamental biology of the disease has evolved, reflecting the human immunodeficiency virus pandemic, increasing world travel, and, as always, poverty. The promise held out by molecular diagnostic technology has yet to deliver in this arena, and antibiotic resistance continues to drive the quest for new antimicrobial agents. The emergence of multidrug-resistant Streptococcus pneumoniae, the microorganism most often implicated as a cause of CAP, continues to threaten treatment options. The evolution of this organism, the persistently high mortality rate associated with CAP, and increasing health-care costs have prompted the publication of guidelines by various authorities that can be used to assist in the initial assessment of the patient and then guide empirical antimicrobial therapy. It is unclear whether these guidelines will have significant impact on cost and mortality, although the trend toward a rational and evidence-based approach to antimicrobial therapy must be a goal to aspire to.